Abstract
Background Macrolides have been widely used to treat moderate-to-severe acne for more than 50 years. However, prevalent antibiotic resistance of Propionibacterium acnes, along with the absence of clinically available resistance tests, has made macrolide misuse a frequent occurrence, with serious consequences.
Objective We developed P. acnes qPCR-based antibiotics resistance assay (ACQUIRE) to enable fast and accurate detection of P. acnes macrolide resistance in clinical settings, representing an opportunity to administer antibiotics more wisely and improve the quality of care.
Methods A cross-sectional observational study was conducted to probe into the macrolide resistance of P. acnes in acne patients.
Results The high sensitivity of ACQUIRE enabled us to reveal a much higher P. acnes 23S rDNA point mutation rate (52%) and thus a higher macrolide resistance (75.5%) compared to previous reports. Carriage of ermX gene was discovered on 472 (53%) subjects, which concurs with previous studies.
Conclusion Macrolide resistance of P. acnes is much higher than previously reported.
Competing Interest Statement
Feizhou Zhu, Jianglin Zhang, Liyu Chen, Jingheng Zhang and Fang Yu reported China Patent 2020101633011, a method that promotes the detection accuracy and efficiency of P. acnes antibiotic resistance.
Funding Statement
China Hunan Provincial Science and Technology Plan (2018SK7005, 2017SK2092); Innovative Education Reform Program of Central South University (2019CG045); National Undergraduate Innovation Training Program of Central South University (201810533233, GS201910533150X); Hunan Science and Technology Innovation Talent Program (To Yiming Xu).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval status: This study is approved by the Ethical Committee of Central South University Xiangya Hospital (No.201801002).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: China Hunan Provincial Science and Technology Plan (2018SK7005, 2017SK2092); Innovative Education Reform Program of Central South University (2019CG045); National Undergraduate Innovation Training Program of Central South University (201810533233, GS201910533150X); Hunan Science and Technology Innovation Talent Program (To Yiming Xu).
Conflicts of Interest: Feizhou Zhu, Jianglin Zhang, Liyu Chen, Jingheng Zhang and Fang Yu reported China Patent 2020101633011, a method that promotes the detection accuracy and efficiency of P. acnes antibiotic resistance.
IRB approval status: This study is approved by the Ethical Committee of Central South University Xiangya Hospital (No.201801002).
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos